WallStreetZenWallStreetZen

NASDAQ: EOLS
Evolus Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

EOLS past revenue growth

How has EOLS's revenue growth performed historically?
Company
35.98%
Industry
10.23%
Market
16.96%
EOLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EOLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EOLS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EOLS earnings and revenue history

Current Revenue
$202.1M
Current Earnings
-$61.7M
Current Profit Margin
-30.5%

EOLS Return on Equity

Current Company
N/A
Current Industry
15.4%
Current Market
188%

Be the first to know when EOLS announces earnings.

EOLS Return on Assets

Current Company
-36%
Current Industry
3.4%
EOLS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

EOLS Return on Capital Employed

Current Company
-33.88%
Current Industry
5.1%
EOLS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EOLS vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
EOLS$202.09M-$41.81M-$61.69M+55.10%N/A
SIGA$139.92M$88.31M$68.07M-21.75%-29.04%
CGC$246.67M-$907.84M-$952.65M+16.69%N/A
PAHC$982.01M$80.57M$14.80M+3.20%-27.12%
PETQ$1.10B$81.00M$2.13M+15.83%N/A
View Top Pharmaceutical Stocks

EOLS earnings dates

Next earnings date
May 7, 2024

Evolus Earnings & Revenue FAQ

What were EOLS's earnings last quarter?

On Invalid Date, Evolus (NASDAQ: EOLS) reported Q4 2023 earnings per share (EPS) of -$0.20, up 16.67% year over year. Total Evolus earnings for the quarter were -$11.83 million. In the same quarter last year, Evolus's earnings per share (EPS) was -$0.24.

If you're new to stock investing, here's how to buy Evolus stock.

What was EOLS's earnings growth in the past year?

As of Q2 2024, Evolus's earnings has grown year over year. Evolus's earnings in the past year totalled -$61.69 million.

What is EOLS's earnings date?

Evolus's earnings date is Invalid Date. Add EOLS to your watchlist to be reminded of EOLS's next earnings announcement.

What was EOLS's revenue last quarter?

On Invalid Date, Evolus (NASDAQ: EOLS) reported Q4 2023 revenue of $61.00 million up 39.76% year over year. In the same quarter last year, Evolus's revenue was $43.65 million.

What was EOLS's revenue growth in the past year?

As of Q2 2024, Evolus's revenue has grown 35.98% year over year. This is 25.75 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.23%. Evolus's revenue in the past year totalled $202.09 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.